Decay of (,)-Fourier coefficients.

We show that essentially the speed of decay of the Fourier sine coefficients of a function in a Lebesgue space is comparable to that of the corresponding coefficients with respect to the basis formed by the generalized sine functions sin .

Clock drawing, clock reading, clock setting, and judgment of clock faces in elderly people with dementia and depression.

Objectives: To assess patient performance on different clock tasks.

Design: Group comparisons.

Setting: A hospital-based memory clinic; inpatient and outpatient memory clinic.

Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites.

The treatment of behavioral disturbances is particularly challenging in patients suffering from dementia. In an 80-year-old female patient with probable AD and severe obsessive and compulsive symptoms, we demonstrated a significant reduction in the density of serotonin transporter sites using 1231-beta-CIT SPECT. Treatment with fluoxetine for 6 months resulted in significant symptom relief and an increasing density of serotonin transporter sites when compared to the beginning of treatment.

Pharmacological treatment strategies of residential primary care providers in dementia diseases--results of a representative survey in western Austria.

Objective: The goal of this study was to investigate pharmacological treatment strategies used by residential primary care providers for patients with dementia.

Methods: A postal questionnaire survey was sent to all residential primary care providers, internists, neurologists and psychiatrists (n = 689) in the western region of Austria.

Results: The response rate (53 %) was similar in all four physician groups.

Synaptic proteins in Alzheimer's disease.

Chromogranin A, chromogranin B, and secretogranin II are acidic proteins which are stored in large dense core vesicles of neurons. An antiserum, raised against a synthetic peptide (PE-11), present in the chromogranin B molecule, and an antiserum raised against secretoneurin contained in the secretogranin II sequence, was used to localize these peptides together with chromogranin A in the human hippocampal formation. The distribution of these peptides was investigated in Alzheimer's disease and compared to control subjects.